These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from Fullerton Wellness had an unidentified "black particulate" floating in it.

Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Eli Lilly And Co LLY experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs ...

The company said sales of Mounjaro and Zepbound were hurt in the latest quarter by wholesalers cutting inventory, after they increased inventory at the end of the previous quarter. Tomi Kilgore is ...

As weight-loss injections emerge as key players in the government’s anti-obesity strategy, Emma Loffhagen goes inside the ...

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...